A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ISM001-055 (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Adverse reactions
Sponsors InSilico Medicine

Most Recent Events

12 Nov 2024 According to an Insilico Medicine media release, Phase IIa data from this study will be presented at an upcoming medical conference and published in reputable medical journals.
12 Nov 2024 According to an Insilico Medicine media release, company will be initiating discussions with regulatory bodies based on these encouraging results and will be pursuing a pivotal trial of ISM001-055 in IPF patients.
12 Nov 2024 Results published in the Insilico Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight